On Wednesday, Krystal Biotech got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97.
Looking For The Best Stocks To Buy And Watch? Start Here
The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Krystal Biotech is not currently near a proper entry. Look for the stock to form and break out of a new base.
The stock earns an 82 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 82% of all stocks.
Its Accumulation/Distribution Rating of D- shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
In Q4, the company posted 407% earnings-per-share growth. Sales growth came in at 116%, down from 879% in the previous quarter. The company's next quarterly report is expected on or around May. 6.
Krystal Biotech holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
